| Consolidated net income |
-632.41M |
| Depreciation and amortization |
255.66M |
| Stock-based compensation |
39M |
| Amortization of debt issuance costs and premium / discount |
36.26M |
| Selling, general and administrative expenses paid in shares of common stock |
268K |
| Deferred income taxes |
| (Gain) loss on disposal of property, plant and equipment |
2.57M |
| Change in the fair value of acquisition-related contingent consideration |
| Loss on extinguishment of debt |
11.31M |
| Loss on auction-rate securities rights |
| Gain on trading securities |
| Impairment of other indefinite-lived intangibles |
680.2M |
| Accounts receivable |
-80.2M |
| Inventories |
-29.29M |
| Prepaid and other assets |
-23.6M |
| Accounts payable |
-159.53M |
| Accrued expenses |
-167.11M |
| Other liabilities |
487.63M |
| Income taxes payable/receivable |
31.83M |
| Net cash provided by operating activities |
298.52M |
| Purchases of property, plant and equipment |
-96.48M |
| Proceeds from sale of property, plant and equipment, net |
1.86M |
| Proceeds from sales of trading securities |
| Acquisition, net of cash acquired |
-3.65M |
| Other investments |
-770M |
| Payment on contingent consideration |
-5M |
| License fees |
-12M |
| Net cash [(used in) provided by] investing activities |
-883.64M |
| Capital lease obligations repayments |
-457K |
| Tax benefits of stock awards |
12.02M |
| Exercise of Endo Pharmaceuticals Holdings Inc. Stock Options |
97.13M |
| Proceeds from issuance of 2019 and 2022 Notes |
| Purchase of common stock |
0 |
| Proceeds From Issuance Of Debt |
0 |
| Principal payments on Term Loan |
0 |
| Payment on AMS Convertible Notes |
| Deferred financing fees |
| Distributions to noncontrolling interests |
-52.71M |
| Buy-out of noncontrolling interests, net of contributions |
-1.49M |
| Proceeds from other debt, net |
1.25M |
| Net cash [provided by (used in)] financing activities |
579.53M |
| Effect of foreign exchange rate |
1.69M |
| NET INCREASE IN CASH AND CASH EQUIVALENTS |
-3.91M |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
529.69M |
| CASH AND CASH EQUIVALENTS, END OF PERIOD |
526.6M |
| Cash paid for interest |
128.45M |
| Cash paid for income taxes |
70.16M |
| Purchases of property, plant and equipment financed by capital leases |
497K |
| Accrual for purchases of property, plant and equipment |
8.35M |
